products-page-bottom-left-box

Trexip 500

Greenlife Pharmaceuticals Ltd
2, Bank Lane, Off Town Planning Way, Ilupeju, Lagos State, Nigeria
Email: info@greenlifepharmaceuticals.com, greenlife2001@yahoo.com
Tel: 01-737-8991; 01-871-3181; 0803-343-1338; 0803-569-9324

Brand Name

Trexip 500

Manufacturer

Greenlife Pharma Ltd, Lagos, Nigeria.

Therapeutic Class

Antibacterial, Quinolones

Dosage Form, Composition & NAFDAC Registration Number (NRN)

Tablet (NRN: 04-5321): Each film-coated tablet contains: Ciprofloxacin HCl USP equiv. to Ciprofloxacin 500 mg.

Pack size: Alu Alu blister of 10 tablets in a carton.

Pharmacology

Trexip 500 is a bacterial DNA-gyrase inhibitor. Its action is highly selective as eukaryotic cells are 10-100 times less sensitive. It is usually rapidly bactericidal for susceptible bacteria.

Indications

Trexip 500 is suitable for treating infections caused by Ciprofloxacin-sensitive pathogens such as:

  • Urinary tract infections, except prostatitis;
  • Urethritis, cervicitis, gonorrhoea;
  • Gastrointestinal tract infections including typhoid fever and paratyphoid;
  • Respiratory tract infections, except pneumonia caused by Streptococcus;
  • Skin and soft-tissue infections;
  • Bone and joint infections.

Contra-indications

Hypersensitivity to quinolone derivatives.

Precautions/Warnings

Trexip 500 is not effective against anaerobic infections. Its effectiveness in respiratory infections caused by Streptococcus pneumoniae is not established. Resistance has emerged in long-term treatment of respiratory tract infections caused by P. aeruginosa in patients with cystic fibrosis. This drug is not effective in preventing pneumonia caused by Pneumocystic carinii.

Cerebral arteriosclerosis and epileptic patients are prone to the central nervous system reaction of this drug.

This drug is not recommended for use in pregnant or lactating women and prepubertal children because it has produced erosion of the cartilage in weight bearing joint and other arthropathy in immature animals.

Interactions

Trexip 500 increases plasma Theophylline concentrations, presumably by interfering with its hepatic metabolism.

Decreased Ciprofloxacin absorption occurs when co-administered with Magnesium-Aluminum antacids.

Adverse Effects

Trexip 500 generally have been well tolerated and adverse reactions seldom were severe enough to require discontinuation of therapy. Adverse reactions most frequently have affected the gastrointestinal tract and central nervous system. Nausea, headache and dizziness have occurred most commonly.

Adverse effects on the gastrointestinal tract include abdominal pain, dyspepsia, flatulence, vomiting, diarrhoea and stomatitis.

Additional adverse reactions affecting the central nervous systems include malaise, drowsiness, weakness, insomnia, restlessness and agitation.

Depression, hallucination, vision disorder, psychosis and convulsion have been reported rarely.

Dosage & Administration

Adults:

Urinary tract infections: mild to moderate, 250 mg every 12 hours; severe, 500 mg every 12 hours.

Respiratory tract, bone and joint, skin infections: mild to moderate, 500 mg every 12 hours; severe, 750 mg every 12 hours.

Bacterial diarrhoea: 500 mg every 12 hours.

The usual duration of therapy is 7-14 days but more prolonged therapy may be required for severe and complicated infections.

Bone and Joint infections may require treatment for 4-6 weeks or longer.

Infectious diarrhoea may be treated for 5-7 days.

For acute gonorrhoea: urethral, endocervical, rectal or pharyngeal: a single dose of 500 mg.

Trexip 500 is preferably taken 2 hours after meals with plenty of water.

Storage/Handling Recommendations

Keep in a cool, dry & dark place.

Keep medicines out of reach of children.

Review Date

2015-04-05 04:50:35